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Abstract We propose a hybrid sequential deep learning model to predict the risk of AMD 
progression in non-exudative AMD eyes at multiple timepoints, starting from short-term 
progression (3-months) up to long-term progression (21-months). Proposed model combines 
radiomics and deep learning to handle challenges related to imperfect ratio of OCT scan dimension 
and training cohort size. We considered a retrospective clinical trial dataset that includes 671 
fellow eyes with 13,954 dry AMD observations for training and validating the machine learning 
models on a 10-fold cross validation setting. The proposed RNN model achieved high accuracy 
(0.96 AUCROC) for the prediction of both short term and long-term AMD progression, and 
outperformed the traditional random forest model trained. High accuracy achieved by the RNN 
establishes the ability to identify AMD patients at risk of progressing to advanced AMD at an early 
stage which could have a high clinical impact as it allows for optimal clinical follow-up, with more 
frequent screening and potential earlier treatment for those patients at high risk.  
Introduction 
Age-related macular degeneration (AMD) is the leading cause of visual loss in developed countries 
with an aging population. It can be characterized by few symptoms in the early stages but can 
progress to sudden and severe visual impairment in a late stage[1]. The worldwide prevalence of 
early stages of AMD in patients between 45 and 85 years is 8% (95% credible interval [3.98–
15.49]) and of late AMD is 0.4% (95% credible interval 0.18–0.77)[2]. Prevalence increases with 
age, reaching 30% for early and 7% for late AMD among those aged 85 years old. Given the 
increase in life expectancy, nearly 200 million people are expected to have AMD by 2020 and 288 
million by 2040. AMD stages can be mainly characterized as “dry” and “wet”. Dry AMD is a non-
exudative stage with a slow progressive dysfunction of the retinal pigment epithelium (RPE), 
photoreceptor loss, and retinal degeneration. Early AMD always appears in the dry form 
characterized by drusen, accumulations of extracellular material that build up between Bruch's 
membrane and the RPE. This early manifestation can suddenly progress to a non-exudative 
advanced stage by the appearance of geographic atrophy (GA) or to wet AMD, an exudative stage 
characterized by the growth of abnormal blood vessels underneath the retina (choroidal 
neovascularization, CNV) that can leak fluid and blood, leading to swelling and damage of the 
macula. For simplicity, this article refers to “AMD progression” as the first occurrence of a CNV 
or an exudative event, where a dry AMD patient converts to a wet stage. Eyes can convert from 
dry to wet AMD suddenly, where 90% of patients whose disease progresses to wet AMD may lose 
vision[3]. While no proven treatment exists for advanced AMD in its dry form, early therapeutic 
intervention with injections is imperative for wet AMD, which makes the effective identification 
of possible AMD progression highly dependent on regular monitoring through imaging and vision 
screening. Early detection and intervention in advanced wet AMD have been shown to improve 
visual outcomes. Moreover, identifying the risk of AMD progression at a given time would allow 
for optimal clinical follow-up, with more frequent screening, and potential earlier treatment, 
leading to better clinical outcomes in high-risk patients.  
Recent machine learning studies[4], [5] utilized genetic information to predict the risk of 
AMD with high accuracy, showing an area under a receiver operating characteristic curve (AUC) 
of around 0.8. Studies[6] aiming to predict the progression to advanced AMD integrating genetic 
and clinical data even led to AUCs of around 0.9, showing that the combination of genetic and 
clinical variants are highly significant for the prediction of AMD progression. However, these 
models mainly showed success in predicting long-term risk AMD progression (>5-years). 
Additionally, differences in population genetics may limit the application of current prognostic 
genetic tests as the majority of AMD genetic associations so far have been studied mainly in 
populations of European ancestry. These findings suggest the need of additional gene variant 
studies in AMD extending to different populations.  In addition to genetic profiling, appropriate 
individual demographic data is required if individual risk profiles are to be appropriately 
generated.  
Different imaging modalities produce high resolution retinal images disclosing phenotypes 
that may be good alternatives as non-genomic biomarkers for AMD progression and therapy 
response. Optical coherence tomography (OCT) is an in vivo imaging method capable of resolving 
cross-sectional retinal substructures, and the spectral-domain OCT (SD-OCT) represents a gold 
standard in diagnostic imaging and management of macular diseases given its very fast scanning 
(more than 20,000 axial scans per second) over a retinal area, with axial resolutions as low as 5 
μm. The high acquisition speed and sensitivity of SD-OCT allows the collection of high-resolution 
three-dimensional (3D) scans while minimizing artifacts due to patient movement or ocular 
contractions. Previous studies indicate that a degenerative retinal process is associated with the 
volume of drusen observed in SD-OCT imaging[7], and many other characteristics quantified via 
SD-OCT may be useful as disease biomarkers. Specific methods of artificial intelligence (machine 
learning and deep learning) are being increasingly used for automated image analyses in SD-
OCT[8]. For instance, traditional machine learning techniques[9]–[13] were used to quantify of 
specific disease features, and these techniques could also be used for identification of hidden 
patterns that can be used to improve the prognosis or response to treatment more efficiently. 
Studies using deep learning[14], [15] have shown to be effective for classifying normal versus 
AMD OCT images by directly analyzing the image pixel data. Regarding the prediction of AMD 
progression based on OCT image biomarkers, two main studies have been published 
previously[11], [16]. These studies propose an initial solution for the prediction of wet AMD using 
traditional machine learning techniques with limited accuracy (0.74 and 0.68 AUC). Yet, none of 
the predictive models considered sequential learning on the longitudinal OCT data captured during 
multiple visits.  The predictive performance could be improved by using a sequential deep learning 
model that considers multiple visits of the same patient in an end-to-end model to predict patient-
specific trends in short- and long-term progression of AMD.  
However, a practical challenge for implementing such a sequential deep learning model 
for processing longitudinal raw SD-OCT images is that a single SD-OCT volume typically 
contains from 100 to 200 two-dimensional (2D) high-resolution images (B-scans), which makes 
the input data dimension extremely large (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑠𝑖𝑡𝑠 × 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓𝐵 − 𝑠𝑐𝑎𝑛 𝑖𝑚𝑎𝑔𝑒𝑠 ×
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑖𝑥𝑒𝑙 𝑖𝑛 𝑒𝑎𝑐ℎ 𝑖𝑚𝑎𝑔𝑒) to be handled in a computationally efficient way. A deep 
learning model that can handle such a complex data space needs huge amount of training data to 
suppress optimistically biased evaluations of the performance. As a general rule of thumb, the size 
of dataset should be at-least about 10x its dimension, which is impractical for most of the 
longitudinal clinical prediction cases, given the limitation of data availability.        
To overcome these challenges, we proposed a hybrid modeling approach, which integrates 
radiomics image features [17] and deep learning in the same platform by extracting the radiomics 
features from the longitudinal OCT scans and feeding them into a sequential deep learning model 
for temporal prediction of AMD progression. We analyzed a longitudinal OCT scan dataset of a 
total of 671 fellow eyes with 13,954 non-neovascular observations using both traditional machine 
learning and a sequential deep learning technique. We aimed to predict AMD progression at 
varying time frames, starting from 3 months (short-term) up to 21 months (long-term). Our study 
provides an interesting insight about the comparative performance of deep learning and traditional 
machine learning approaches for sequential AMD progression prediction (see Overall 
performance). We also compare the models in a visit variant setting that represents the model 
performance at a very early point of the sequence and also at a late point, when the model has 
already learned the trend of the patient by analyzing the previous visit sequence (see Visit-variant 
performance).   
Results 
Study Dataset 
This study was a retrospective, post hoc analysis of the fellow eye of participants from the 
HARBOR trial (ClinicalTrials.gov identifier: NCT00891735) [18], a 24-month, phase III study 
conducted at 100 investigator sites that evaluated the efficacy and safety of 2 doses and 2 regimens 
of ranibizumab in 1097 patients aged ≥50 years. Patients in this study were selected to have CNV 
lesions with classic CNV component or occult CNV in the study eye at baseline. All patients had 
monthly evaluations of both study and fellow eyes with SD-OCT imaging following a standardized 
protocol acquired with a Cirrus HD-OCT device (Carl Zeiss Meditec, Inc., Dublin, CA, USA) 
using one of the two following macular scanning protocols, both covering a volume of 6 × 6 × 2 
mm3: 512 × 128 × 1024 voxels with a size of 11.7 × 47.2 × 2.0 μm3; or 200 × 200 × 1024 voxels 
with a size of 30.0 × 30.0 × 2.0 μm3. 
Out of the 1097 patients considered in the HARBOR study 686 fellow eyes were graded 
as non-neovascular at baseline and were considered in this work. Fellow eyes were determined to 
be non-neovascular at baseline if no neovascular AMD was reported from the eye history case 
report forms and if no CNV was present at baseline. From this set of fellow eyes, a number of the 
monthly OCT scans were excluded due to complications linking the OCT data to the clinical 
diagnosis data resulting from the anonymization process. No quality measures were further 
considered to exclude any of the remaining images.  
The remaining imaging data considered consisted on 686 fellow eyes with a total of 32670 
OCT scans. Multiple fellow eyes had several OCT scans acquired during the same imaging session 
(same date), often acquired using a combination of the two described scan patterns. Imaging 
features (quantification of any of the properties described in Materials and Methods) extracted 
from OCT scans acquired during the same imaging session where averaged by taking their mean 
value and considered as a unique observation. OCT scans after a CNV or exudation event (AMD 
progression) were excluded from the analysis since this work aims to identify features as 
biomarkers before such events. If no OCT scan from a fellow eye was retrieved before an eventual 
event, the fellow eye was dropped from the study. AMD progression was determined if a fellow 
eye that was non-neovascular at baseline received any treatment for exudative AMD at any point 
during the 2year follow-up. This study then considered a total of 671 fellow eyes with 13,954 non-
neovascular observations at unique times prior to progression. Of the 671 fellow eyes, 149 eyes 
presented progression before the end of the study, while the remaining 522 did not. 
Outcome labeling 
The observations collected from the OCT data were labeled according to the occurrence of a 
progression event within a given time frame or the certainty of no event within that time frame. 
Considering a given time, an observation was labeled with a positive outcome (“progressor”) if 
treatment was recorded for that particular eye within that given time elapsed from the observation. 
On the other hand, an observation was labeled with a negative outcome (“non-progressor”) if 
treatment was not received for that particular eye within the given time frame and there was a 
subsequent observation of the same eye after the given time where there was no treatment received 
(no evidence of CNV or exudation). If an observation had no history of treatment within the given 
time frame and there was no evidence of lack of CNV or exudation after the time frame (either 
because the end of the study time or missing data), the observation was dropped from the study for 
that analyzed time, since there were no guarantees that the eye did not progress within that time. 
Seven different time frames were analyzed in this study, ranging from 3 months to 21 
months within the observation time in 3-month increment intervals. The distribution of number of 
observations at each given category (progressors and non-progressors) is shown in Fig. 1. As 
shown, the number of total observations as well as the number of non-progressor observations 
reduces for longer time intervals due to the length of the study, where observations acquired in the 
later months of the study duration had no future information available in the longer time intervals 
(for example, an observation collected at month 12 of the study from an eye that did not develop 
exudation during the study had future information within 3 months, but not within 21 months due 
to the 24-month total study time). It can also be seen that the number of progressor observations 
increases for longer time intervals, as observations that progressed within a short interval (for 
example, 3 months) were also considered to progress within a longer time interval (for example, 6 
months).     
 
 Fig. 1. Study dataset distribution. Distribution of number of observations and outcomes 
considered for each of the time intervals analyzed in this study. The “progressors” label indicates 
a recorded progression event within the given time frame. The “non-progressors” label indicates 
certainty of not having an event within the given time frame. 
Training and testing scheme 
Given the limited size of the study dataset, Random Forest and RNN models were evaluated in a 
10-fold cross validation scheme, where the original sample (13,954 time points of 671 patients) 
was partitioned into 10 equal sized subsamples. The same proportion of progressing/non-
progressing eyes was kept in each of the subsamples. We created a patient level separation while 
dividing the data in subsamples, where we train the model on the observations from 604 patients, 
and the observations from 67 patients are held out for validation. The patient level separation 
approach gives us more stringent evaluation of the model since we completely isolated the 
validation from the training set. Of the 10 subsamples, a single subsample of size roughly 1,395 
time points is retained as the validation data for testing the model, and the remaining 12,559 
subsamples are used as training data. The cross-validation process is then repeated 10 times, with 
each of the subsamples used exactly once as the validation data. The same 10-fold partitions were 
used to evaluate the RNN and Random forest model to provide a fair comparison between the two 
models.  
As a primary metric, the accuracy of the prediction was evaluated by the Receiver 
Operating Characteristic (ROC) curve. ROC curve is a well-accepted method to show the trade-
off between true-positive and false-positive prediction rates, where the models produce a 
probability scores for test samples, and present pairs of specificity and sensitivity values calculated 
at all possible threshold scores. These rates are irrespective of the actual positive/negative balance 
on the test set, and thus the ROC is insensitive to class distribution. The ROC curve also provides 
a single performance measure, the Area under the ROC curve (AUC) score, where AUC 1 
represents a perfect prediction and 0.5 represents a random prediction.  
Predictive performance: Deep learning and traditional machine learning approaches 
We first evaluated the prediction models by considering the total number of observations (see 
Overall performance). For instance, if a patient has ten unique observations (visits at a given time 
point), 10 predictions are considered in the analysis whereas 2 predictions are considered for 
patients with two observations. Each visit is considered as an individual data point that includes 
features extracted from that particular visit and information from the previous visits of the same 
patient. 
In order to understand the dependency of the model’s performance with the number of 
historic visits considered, we also investigated the performance of Random Forest and Deep 
learning model (RNN) in a Visit-variant setting (see Visit-variant performance). We started the 
evaluation from 2 visits (1 current and 1 historic) to 16 visits (1 current and 15 historic) from the 
same eye and evaluated the performance of the models for 3 months up to 12 months in the AMD 
progression prediction task. 
Overall performance 
Side-by-side performance of the models in terms of AUC-ROC curve is shown in Fig. 2 using the 
same fold partitions. All the visits are considered as unique data point for this evaluation. We 
present the ROCs for all 10 folds as well as mean ROC (thick blue line). Being trained on the same 
OCT features, the RNN model performance is consistently better than the Random Forest model 
for all the prediction tasks with reasonably low variations between the folds. For instance, the 
mean AUC of RNN is 0.96 +/- 0.02 for prediction of AMD progression within 3 months from the 
visit while Random Forest scored 0.64 +/- 0.06 mean AUC. The high accuracy of the RNN model 
for both short and long-term progression suggests that it was able to integrate patient-specific 
demographics and imaging information by preserving long-term dependencies via the sequence-
dependent temporal modeling.  We observed a significant drop of RNN performance (p-value 
>0.05) for prediction of AMD progression within 12 months (0.77 mean AUC) compared to within 
3 months, which improved for the 18 months. The performance drop could be due the fact that a 
fewer  number of sequential visit data were available for model training, while characteristics of 
the progressor and non-progressor classes were quite close, which makes optimization of the 
prediction decision boundary the most difficult for the 12 months’ time point. However, the 
performance improves   at the 18 and 21 month time points, even with less data, since the training 
dataset is more balanced, while more diverse characteristics can be observed between long-term 
progressor and non-progressor classes. 
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Fig. 2: Side-by-side performance evaluation for Random Forest and RNN prediction model as 
ROC curve. Performance of Random Forest is presented in left and RNN model is presented in 
right.  
Visit-variant performance 
Using the same training and testing separation, we validated both prediction models in a visit 
variant setting and show the AUC-ROC values in Fig. 3, where x-axis shows the number of visits 
and y-axis shows the AUC-ROC values. We present the performance for even number of visits 
from 2 up to 16. The reported performance shows that the Random Forest model’s performance is 
not varying much with the number of historic visits while RNN prediction performance improves 
by increasing the number of historic visits. For instance, RNN performance increased from 0.64 
up to 0.8 AUC-ROC for short-term progression prediction (within 3 months) by increasing the 
number of visits from 2 to 6, and from 0.68 up to 0.96 for long-term progression prediction (within 
12 months) by increasing the number of visits from 2 to 16 visits.      
The improvement in RNN performance is likely due to the fact that the model understands 
the patient’s current eye status better based on its understanding of previous visits by capturing 
long-term dependencies in visit sequences and, providing more historic visits, enhances the 
model’s insight about the patient. Given this, the RNN prediction model is expected to perform 
better when a patient has more follow-up visits. However, with only 2 visits, the RNN model 
performs better than the Random Forest model for all the prediction tasks, which shows that even 
with little historic knowledge about the patient, the proposed RNN model can predict the 
progression of AMD better than the traditional model. This has potential clinical impact, since 
patients may not have data from many prior visits available.  
 
 
 Fig. 3. Visit-variant performance evaluation for Random Forest and RNN prediction model: 
blue colored lines shows the Random Forest performance and orange colored lines shows the 
RNN performance. 
Discussion 
In this study, we proposed a sequence-dependent hybrid prediction model that, given a sequence 
of patient visits, can efficiently predict the probability of an exudative or CNV event from early 
and intermediate AMD (AMD progression) at different timepoints (within 3 months up to 21 
months in 3 months intervals). The study showed a way of integrating advanced radiomics 
methods[17] with sequential deep learning for analyzing longitudinal clinical visit data to make 
prediction about disease progression. The engineered OCT features extracted by our radiomics 
pipeline allowed the proposed RNN model to focus only on the relevant predictors (e.g. druse 
volume, area) rather than raw pixel data, and discover complex relationships within sequence of 
visits by applying a long-term dependency learning between the predictors. The deep learning 
model was compared against a traditional random forest model that used the same available data 
to make a prediction based on a combination of demographics and quantitative image features. 
Both models were trained and evaluated in a cross-validation setting on 13,954 observations from 
671 fellow eyes of patients considered in the HARBOR study. 
Being trained on the delta features (difference between current and historic feature values), 
the Random Forest model scored 0.66+/- 0.07 AUC for short-term (within 3 months) AMD 
progression prediction, while scoring 0.83+/-0.03 AUC for long-term (within 21 months) 
prediction. It can be observed that prediction for longer time intervals was more accurate than for 
shorter time intervals. These results are superior to those obtained in a previous study[16] using 
the same dataset as employed here. While previous study only aimed to predict the probability of 
progression at the end of the study considering the observations up to the fourth month of the 
study, this translates to a prediction of AMD progression within 20 months and reported an AUC 
of 0.68 for predicting a CNV or exudation event. We hypothesize that the differences in 
performance may be a result of the different algorithm employed to automatically segment the 
OCT data in order to extract the imaging features, a different model used for the prediction (a Cox 
proportional hazards model instead of a Random Forest model) and/or the consideration of all 
possible observations for training the model in this work (use of LTSM units). This previous work 
also considered the genetic data included in the HARBOR dataset and modeled the prediction of 
GA appearance in a similar manner (0.8 AUC). Inclusion of genetic data as part of our models and 
expanding the ability of the models to predict GA appearance was not done here and will be a 
matter for future work.  
The proposed RNN model out-performed the Random forest model by predicting short-
term (within 3 months) AMD progression with 0.96+/-0.02 AUC and long-term (within 21 
months) progression with 0.96+/-0.02 AUC. The high prediction accuracy suggests that the 
proposed model learns the complex longitudinal relation between the combination of demographic 
and visual factors and imaging features by analyzing a sequence of visits and can establish the 
correlation with both short-term and long-term AMD progressions. Visit-variant performance 
evaluation demonstrates an interesting insight that having many follow-up patient visits can boost 
the performance of the prediction model by learning patient-specific temporal trends. For instance, 
in the same setting, the performance upgraded from 0.64 to 0.89 AUC-ROC for short-term follow-
up by increasing the number of visits from 2 to 16.         
The American Academy of Ophthalmology recommends comprehensive eye examinations 
with OCT imaging every three months in patients more than 65 years of age with risk of AMD 
progression. Such longitudinal ophthalmic images are ideal for training a machine learning model 
to diagnose blinding eye diseases earlier and prevent disease progression by analyzing current and 
historic data. It has also been shown that demographic factors, like gender, age and smoking 
history, are confounding factors for AMD progression. Analysis of OCT images to predict 
progression of AMD has been recently applied to improve early diagnosis and prevention.  de 
Sisternes et al [11], were among the early scientists to automatically extract drusen features from 
SD-OCT images to predict future AMD progression from an early or intermediate nonexudative 
stage (dry AMD) to an advanced exudative stage (wet AMD). However, previous studies did not 
consider quantitative image features, demographic, and visual factors from each sequential visit 
directly, but only considered the linear trend of the features from historic data (as done in the 
Random Forest model employed here). In the current study, we proposed a recurrent neural 
network which takes a long-sequence of visits as input for computing risk for AMD progression 
by remembering relevant information across long periods of time.    
We consider the following three points as key limitations of our study. 
i. Trained and validated on the same clinical trial dataset - The OCT data on eyes 
analyzed for the progression of AMD come from a single clinical trial, which is an artificial 
setting with bias selection criteria for the observations. Therefore, the dataset may not 
represent real-world patient data which may affect the generalizability of the model to an 
independent dataset. However, the high accuracy achieved by our RNN model in two 
different settings suggests that the model may able to predict AMD progression given the 
successful extraction of 21 imaging biomarkers. We adopted a standardized pipeline 
(segmentation and feature extraction) to handle the OCT images to ensure satisfying 
biomarker extraction performance. It is also important to note that the features used in the 
modeling were averaged through multiple scans collected at a single imaging session (an 
average of 2.02 scans per session). The acquisition of multiple scans may not be typical of 
clinical practice and may have added to the stability of the extracted features. The 
performance of the model considering only a single acquisition per imaging session in a 
separate dataset will be matter of study in upcoming future work.      
ii. Limited size of the observations - For machine learning, an interesting and almost linear 
relationship can be observed between the amount of training data required and the 
complexity of the model, with the basic reasoning that the model should be large enough 
to capture relations in the data along with specifics of the targeted task. In our study, the 
RNN and random forest models were trained and validated on a limited number of 
observations - 13,954 time points of 671 patients, which can be considered as a limitation 
of the study. Thus, we restricted the learning parameters (neuron weights) of the RNN 
model to minimal count. However, the prospective data collection allowed us to represent 
significant samples for training. Additionally, we applied a data augmentation method to 
train the RNN model.     
iii. Limited explain-ability - Given the complexity of the data (visit + imaging features) and 
the use of deep learning models, it is not trivial to explain the basis for predictions made 
by the models. For instance, in the RNN model, learned weights of the neurons can provide 
insights into the usefulness of the features, but it can also be biased by the combination of 
historic visit data. On the other hand, Random forest is popular for feature ranking, but 
these models may be challenged when data interpretation is important. With correlated 
features, strong features can end up with low scores and the method can be biased towards 
variables with many categories. 
 
Materials and Methods 
 
The OCT imaging/demographic data used was curated from a previously acquired longitudinal 
dataset that includes several OCT scans at different time points and a set of demographic features. 
The variables used in this study were previously described as indicators of possible disease 
progression[11] and were considered to train and evaluate two different models for the prediction 
of a CNV or exudative event from a non-neovascular AMD diagnosis: (i) A traditional model 
using Random Forest, and (ii) A deep learning predictive model using Recursive Neural Network 
(RNN).  
Demographic Factors 
A set of 5 demographic and visual features were considered in our analysis. These features were 
collected as part of the HARBOR dataset and included the following (as listed in Table 1): Age, 
gender, race, smoking status and visual acuity at baseline. Table 1 contains the average and 
standard deviation values for these features at the time of the first OCT observation available per 
patient. 
Table 1: List of demographics considered in our analysis. Contains average and standard 
deviation (std) values at first available OCT observation overall and for fellow eyes with/without 
a progression event (progressors/non-progressors) during the study. 
Demographic 
Feature 
Description All fellow eyes 
(N=671) 
Progressors 
(N=149) 
Non-
progressors 
(N=522) 
Age Age of the patient in months at baseline 
mean (std) 
78.2 (8.3) 79.5 (7.7) 77.8 (8.4) 
Gender Patient gender: Male/Female % 40.4 / 59.6% 30.2 / 69.8% 43.3 / 56.7% 
Race Patient Ethnicity:  American or Alaska 
native / Asian / Black or African 
American / White / Native Hawaiian or 
Pacific Islander / Multiracial 
0.3 / 1.6 / 0.4 / 
96.9 / 0.3 / 0 %  
0 / 0.7 / 0 / 
98.7 / 0.7 / 0 
% 
0.4 / 1.9 /  0.6 / 
96.4 / 0.2 / 0 % 
Smoking status Smoking status: Non-smoker / Previous 
smoker / Current smoker 
41.0 / 48.4 / 
10.6 % 
38.9 / 47.0 / 
14.1 % 
41.6 / 48.8 / 9.6 
% 
Visual Acuity Visual acuity at baseline of observation 
measured in LogMAR scale 
76.07 (13.07) 76.91 (9.31) 75.83 (13.96) 
 
Extraction of imaging biomarkers  
A set of 21 imaging features describing presence, number, extent, density and relative reflectivity 
of drusen were extracted directly from each SD-OCT volume (Table 2). Drusen characteristics 
were computed automatically in a similar manner as studied as predictors of AMD progression in 
a previous publication[11]. Each OCT volume was processed using proprietary Cirrus Review 
Software (Carl Zeiss Meditec, Inc., Dublin, CA, United States) to automatically segment the 
location of the Retinal Pigment Epithelium (RPE) in the form of a surface and to generate a 
topographic map describing the regions of substantial RPE elevation (known as “Advanced RPE 
Analysis” in Cirrus Review Software). The location and extent of individual druse were also 
automatically segmented for each OCT volume using previously published methods [12], taking 
the segmented location of the RPE layer and an estimation of the inner segment/ outer segment 
junction (20 microns inner to the RPE locations) as inputs to automatically outline drusen within 
the volume. The result of this processing is a topographic map indicating RPE elevation with 
respect to a Bruch’s membrane (BM) estimation (obtained from Cirrus Review Software) and the 
three dimensional segmentation of drusen locations for each considered OCT volume (obtained as 
described in [12]), where each individual druse is outlined. For a visualization of the segmentation 
results see Fig. 4. 
 
 Fig 4. Imaging biomarker extraction. Image shows a 3-D surface view of segmented drusen, with 
the estimation of BM surface indicated in green color and the detected druse regions identified in 
magenta. Druse identification in a volumetric manner allows the characterization of its volumetric 
properties. The image in the left shows a topographic view of a druse elevation map with individual 
drusen indicated in magenta (the blue square identifies a region shown in detail). The dotted green 
and yellow lines indicate B-scan locations shown in the right side. This topographic view allows 
the characterization of druse area, extent and density properties. The image in the right shows the 
individual druse segmentation in two example B-scans, with generated druse outlines shown in 
magenta. The blue square identifies a region shown in detail, where indications of drusen height, 
slope and reflectivity are shown. Consideration of the B-scan data allow the characterization of 
reflectivity properties inside druse regions. 
 
The topographic RPE elevation map and individual drusen delineations were processed to generate 
the set of features describing the number of independent drusen in SD-OCT volume, mean area 
per druse, total area occupied by drusen in topographic map, extent of topographic region affected 
by drusen (computed by generating the convex hull of the regions affected by individual drusen), 
drusen density in topographic map (computed as the ratio between the area occupied by drusen 
and the total region affected by drusen[11]), total drusen area within 3mm from the fovea center, 
and total druse area within 5mm from the fovea center. 
 The collection of B-scans within the SD-OCT volume and the corresponding three 
dimensional segmentation of drusen locations within the volume was processed to generate the 
following features: mean volume per druse, total volume occupied by drusen, maximum height 
with respect to BM observed for any druse in the collection of B-scans, average druse slope 
(computed as the gradient of drusen height with respect to BM), average relative reflectivity in the 
B-scans within regions delineated as drusen and standard deviation (std.) of the relative reflectivity 
in the B-scans within regions delineated as drusen. The relative reflectivity values were computed 
by normalizing the collection of B-scans so that the 95 percentile pixel value from the collection 
took a value of 1 and the 5 percentile took a value of 0. Since the RPE layer typically presents the 
highest reflectivity within the retinal layers in the scan and the vitreous region presents the lowest 
reflectivity, these values indicate a reflectivity ratio normalized between vitreous and RPE 
reflectivity as measured by the OCT system. 
 In addition, 6 druse features were also collected as reported automatically from the 
“Advanced RPE analysis” function in Cirrus Review software (Carl Zeiss Meditec, Inc., Dublin, 
CA, United States): area and volume within 3mm from the fovea center, area and volume within 
5mm of fovea center, and total area and volume in scan field of view. These druse area and volume 
analyses differ from the previous olatlargerne in terms that the direct output from the Cirrus review 
software was considered here, whereas the individual druse segmentations computed as in [12] 
were considered in the previous analysis.  
Table 2: List of imaging features 
Image Features  Description 
Number of drusen Number of individually separated drusen within OCT volume 
Druse mean volume Average volume occupied by each individual druse within the OCT volume (in mm3/druse) 
Druse total volume Total volume occupied by all drusen within the OCT volume (in mm3) 
Druse mean area Average area occupied by each individual druse within the OCT topographic map (in 
mm2/druse) 
Druse total area Total area occupied by all individual druse within the OCT topographic map (in mm2) 
Extent of druse area Total area affected by druse regions (convex hull of detected individual druse regions) 
within the OCT topographic map (in mm2) 
Druse density Density of drusen in affected regions (Feature#10/Feature#11) within the OCT topographic 
map 
Maximum druse 
height 
Maximum height of drusen with respect Burch’s membrane observed in collection of OCT 
B-scans (in mm) 
Avg. druse slope Average drusen slope (gradient of drusen height) within the OCT volume 
Avg. druse 
reflectivity 
Average value of normalized pixel intensity (values 0-1) inside drusen regions observed in 
collection of OCT B-scans 
Std. druse 
reflectivity 
Standard deviation of normalized pixel intensity (values 0-1) inside drusen regions observed 
in collection of OCT B-scans 
Druse area 3mm Area occupied by the all the individual druse regions in the OCT topographic map within 
3mm from the fovea center (in mm2) 
Druse area 5mm Area occupied by the all the individual druse regions in the OCT topographic map within 
5mm from the fovea center (in mm2) 
Druse volume 3mm Volume occupied by the all the individual druse regions in the OCT volume within 3mm 
from the fovea center (in mm3) 
Druse volume 5mm Volume occupied by the all the individual druse regions in the OCT volume within 5mm 
from the fovea center (in mm3) 
Druse total area 
(Cirrus) 
Area occupied by the all the individual druse regions in the OCT topographic map as 
provided by Cirrus review software (in mm2) 
Druse area 3mm 
(Cirrus) 
Area occupied by the all the individual druse regions within 3mm from the fovea center as 
provided by Cirrus review software (in mm2) 
Druse area 5mm 
(Cirrus) 
Area occupied by the all the individual druse regions within 5mm from the fovea center as 
provided by Cirrus review software (in mm2) 
Druse total volume 
(Cirrus) 
Volume occupied by the all the individual druse regions within the OCT volume as provided 
by Cirrus review software (in mm3) 
Druse volume 3mm 
(Cirrus) 
Volume occupied by the all the individual druse regions within 3mm from the fovea center 
as provided by Cirrus review software (in mm3) 
Druse volume 5mm 
(Cirrus) 
Volume occupied by the all the individual druse regions within 5mm from the fovea center 
as provided by Cirrus review software (in mm3) 
Traditional predictive model: Random Forest 
We employed a Random Forest model to describe the probability of AMD progression within a 
given time frame. Random Forest is a non-linear ensemble learning method that operates by 
constructing a multitude of decision trees based on the analyzed features to predict an outcome[19]. 
Bootstrap-aggregated (bagged) decision trees combine the results of these many decision trees, 
which reduces the effects of overfitting and improves generalization. We constructed 7 
independent models to characterize conversion probability of a given observation within 7 
different time frames: 3, 6, 9, 12, 15, 18 and 21 months from the observation time. Each of the 
trained models employed an ensemble of 200 decision trees, grown using bootstrap samples of the 
data. Gender, race and smoking status were treated as categorical features, while the rest of 
demographic features and imaging features were treated as numerical features. An additional 21 
imaging features were also included characterizing the relative rate of change of each of the 
imaging characteristics along time up to a considered observation. The rate of change was 
computed by fitting a linear function along time for each independent imaging feature listed in 
Table 2, considering the collected previous observations from the same eye up to and including 
the considered observation and reporting the inclination (first coefficient) of the linear fit. 
Each of the models used a regression ensemble[20] where the outcome was the progression 
(1) or non-progression (0) to wet AMD within a given time frame. After the 7 independent Random 
Forest models were trained, the output of the model for an observation not seen in the training data 
was a set of 7 scores ranging from 0 to 1, each describing the probability of progression from 
within 3 months up to within 21 months in 3 month intervals, respectively.    
Deep learning model: Recursive Neural Network (RNN) prediction model 
We designed a many-to-many RNN model (see Fig. 5) using two-layer one-directional stacked 
stateful Long short-term memory (LSTM) units[21] to predict progression from dry to wet AMD 
across the sequence of clinical visits. We chose LSTM because it is relatively insensitive to gap 
length compared to alternatives such as RNNs and hidden Markov models[22]. The long-term 
memory allows slow weight updates during training and encodes general information about the 
whole temporal visit sequence, while short-term memory has an ephemeral activation, passing 
immediate state between successive nodes and resetting itself if a fatal condition is encountered. 
The LSTM includes memory about prior observations (patient visits) and thus accounts for 
longitudinal changes in the patient data. The model takes as input a series of a combined feature 
matrix (𝐹𝑒𝑎𝑡𝑢𝑟𝑒 𝑣𝑒𝑐𝑡𝑜𝑟@𝑂𝑛 in Fig. 5) –consisting of the described demographic and quantitative 
imaging features, ordered according to timestamp of observation where 𝑂𝑛 stands for observation 
at n, and predicts probability of AMD progression. Our objective is to predict AMD progression 
at multiple future timepoints, starting from short-term progression (3, 6, 9 and 12 months), up to 
long-term progression (15, 18 and 21 months); thus, we formulate a set of single time-point 
prediction models. Each RNN model predicts the survival rate at only one time point(𝑇𝑖), and each 
of the seven time points was analyzed by the same architectural model but trained separately.  
 
Fig. 5 Many-to-many LTSM model for predicting progression of AMD 
For each patient (with id 𝑖), the sequence of feature vector is modeled as a series: 𝑋𝑖 =
{𝑥𝑖
1, 𝑥𝑖
2, … … , 𝑥𝑖
𝑛},where each input data observation 𝑥𝑖
𝑡 ∈  𝑅𝐷 is a real-valued vector representation 
of the demographic and quantitative imaging features at the time of observation 𝑡 and n is the total 
number of observations for the patient. Continuous imaging features are mapped to float values, 
and categorical features are also embedded into numeric values. All the features are concatenated 
into one feature vector and passed into the stacked neural network. The targeted AMD progression 
sequence for month 𝑘 of the patient with id 𝑖 is modeled as:  𝑌𝑖 = {𝑦𝑖
1, 𝑦𝑖
2, … . . , 𝑦𝑖
𝑛}, where 𝑦𝑖
𝑡𝜖{0,1} 
is a categorical variable that represents whether the patient will have a progression event within 
month k starting from the observation timepoint. Single directional stacked LSTM units are 
modeled to encode sequence-dependency between the longitudinal visit and predict a probability 
of progression for each time point, following the principle that at the time point 𝑡 the model does 
not have access to the future feature information 𝑥𝑖
𝑡+1 but can access data from the current and all 
the historic time points: {𝑥𝑖
1, 𝑥𝑖
2, … … , 𝑥𝑖
𝑡−1, 𝑥𝑖
𝑡}. A sequence of patient with id 𝑖 with 𝑛 number of 
visit/observation is defined as: 𝑆𝑖
𝑛 = {(𝑥𝑖
1, 𝑦𝑖
1), (𝑥𝑖
2, 𝑦𝑖
2), … , (𝑥𝑖
𝑛, 𝑦𝑖
𝑛)} 
Data augmentation strategy for temporal visit series: Being a supervised machine learning 
approach, our proposed model is limited by the number of available training examples. In this 
study, we explore a simple data augmentation technique (only on the training set) which not only 
boosts the number of training sequences, but also handles varying number of visits for different 
patients. Given a sequence 𝑆𝑖
𝑛 of 𝑛 length, we created 𝑛 augmented sequences 𝐴𝑢𝑔𝑆𝑖
𝑙 of length 𝑙 
by incrementally adding data points at the end of the sequence and padding the rest, where the first 
sequence contains 1 data point (𝑥𝑖
1, 𝑦𝑖
1) and (𝑙 − 1) post-padding points: 𝑃 = (𝑧, 𝑦𝑧), z is a zero 
vector of dimension 𝐷 and 𝑦𝑧 = 2. Similarly, the second sequence contains 2 data points, third 
sequence contains 3 data points, and so on (see Fig. 6).    
 
Fig. 6 Augmentation of the visit sequence for training the neural network model 
In the stacked RNN layers, the first layer’s one directional LSTM block receives the input 𝑥𝑡 and 
previous hidden state ℎ𝑡−1 and passes the current hidden state ℎ𝑡 to the successive LSTM blocks. 
The stacked layers enable more complex representation of our temporal series data, capturing 
information at different scales. The first layer's block also passes the hidden state and current H-
dimensional cell state 𝑐𝑡𝜖𝑅
𝐻 to the corresponding block in the upper layer. The second layer units 
are modeled to maintain the recurrent connections in multiple dimensions. The output estimate 
would be a vector of probabilities across three different labels: 𝐿 = {0, 1, 𝑦𝑧}, where 0 means no 
progression, and 1 stands for progression. The output at each timepoint 𝑡 is modeled as: 𝑦 ?̂? =
𝑠𝑜𝑓𝑡𝑚𝑎𝑥(𝐿. ℎ𝑡), where 𝑦 ?̂? ∈ 𝑅3 is the predicted progression at time 𝑡 and ℎ𝑡 the hidden state of 
the second layer LSTM. The three trainable parameters of each LSTM block are – (i) input-to-
hidden weight matrix: 𝑊𝑥𝜖𝑅
4𝐻×𝐷 (ii) hidden-to-hidden weight matrix: 𝑊ℎ𝜖𝑅
4𝐻×𝐻, and (iii) bias 
vector: 𝑏𝜖𝑅4𝐻. 
During the training phase, our model takes as input the augmented series (𝐴𝑢𝑔𝑆𝑖
𝑙) for all the 
patients present in the training set, and optimizes the time distributed weighted cross entropy loss 
function:  
𝑙(𝑌, ?̂?) = −
1
𝑙
∑(𝑦𝑡𝑙𝑛𝑦 ?̂? + (1 − 𝑦𝑡)𝑙𝑛 (1 − 𝑦 ?̂?)). 𝜆𝑘
𝑙
𝑡=1
  
where 𝑦𝑡 actual reference survival at 𝑡th time point in the sequence, 𝑦 ?̂? represents the output of 
the neural network given the current sequence inputs, 𝜆𝑘𝜖𝑅3 and corresponds to the pre-defined 
weights of the three targeted labels 𝐿. We present a folded configuration in Fig.7 with a layer 1 
LSTM block with 50 hidden neurons and layer 2 block with 20 neurons, where the selection is a 
tradeoff between the input data dimension and the memory requirement for training.  
 
Fig. 7 Architecture of the LSTM model (folded) 
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